Evidence map›Paper›PMID 17208966›Full record

ArticleBiophysical journal2007

Extending Iterative Protein Redesign and Optimization (IPRO) in protein library design for ligand specificity.

Hossein Fazelinia, Patrick C Cirino, Costas D Maranas

Abstract read
In one paragraph

Article in Biophysical journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Forcefield_PTM:Journal of chemical theory and computation · 2013
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Engineering a protein-protein interface using a computationally designed library.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  12. Design and directed evolution of a dideoxy purine nucleoside phosphorylase.Protein engineering, design & selection : PEDS · 2010
    Article
  13. Computational design of Candida boidinii xylose reductase for altered cofactor specificity.Protein science : a publication of the Protein Society · 2009
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hossein FazeliniaDepartment of Chemical Engineering, 112A Fenske Laboratory, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.
Patrick C Cirino
Costas D Maranas

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article we extend the Iterative Protein Redesign and Optimization (IPRO) framework for the design of protein libraries with targeted ligand specificity. Mutations that minimize the binding energy with the desired ligand are identified. At the same time explicit constraints are introduced that maintain the binding energy for all decoy ligands above a threshold necessary for successful binding. The proposed framework is demonstrated by computationally altering the effector binding specificity of the bacterial transcriptional regulatory protein AraC, belonging to the AraC/XylS family of transcriptional regulators for different unnatural ligands. The obtained results demonstrate the importance of systematically suppressing the binding energy for competing ligands. Pinpointing a small set of mutations within the binding pocket greatly improves the difference in binding energies between targeted and decoy ligands, even when they are very similar.

Indexed as

AlgorithmsDrug DesignModels, ChemicalModels, MolecularPeptide LibraryBinding SitesComputer SimulationLigandsMutagenesis, Site-DirectedProtein BindingProtein EngineeringProtein Interaction MappingProteinsSensitivity and SpecificityLigandsPeptide LibraryProteins

Identifiers

PMID17208966
PMCPMC1861794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.